JP2016526885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526885A5 JP2016526885A5 JP2016522479A JP2016522479A JP2016526885A5 JP 2016526885 A5 JP2016526885 A5 JP 2016526885A5 JP 2016522479 A JP2016522479 A JP 2016522479A JP 2016522479 A JP2016522479 A JP 2016522479A JP 2016526885 A5 JP2016526885 A5 JP 2016526885A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cancer
- polypeptide according
- amino acid
- ctla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1311475.6A GB201311475D0 (en) | 2013-06-27 | 2013-06-27 | Polypeptides |
| GB1311475.6 | 2013-06-27 | ||
| PCT/EP2014/063442 WO2014207063A1 (en) | 2013-06-27 | 2014-06-25 | Cd86 variants with improved affinity for ctla-4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526885A JP2016526885A (ja) | 2016-09-08 |
| JP2016526885A5 true JP2016526885A5 (enExample) | 2017-08-03 |
| JP6621741B2 JP6621741B2 (ja) | 2019-12-18 |
Family
ID=48999077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522479A Expired - Fee Related JP6621741B2 (ja) | 2013-06-27 | 2014-06-25 | Ｃｔｌａ−４に対する親和性が改善したｃｄ８６バリアント |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9834589B2 (enExample) |
| EP (1) | EP3013854B1 (enExample) |
| JP (1) | JP6621741B2 (enExample) |
| GB (1) | GB201311475D0 (enExample) |
| WO (1) | WO2014207063A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016500255A (ja) | 2012-12-11 | 2016-01-12 | アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ | ハイスループットなレセプター：リガンド同定の方法 |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| US11008396B2 (en) | 2015-05-21 | 2021-05-18 | Alligator Bioscience Ab | Polypeptides |
| AU2016323069A1 (en) * | 2015-09-14 | 2018-04-12 | Alpine Immune Sciences, Inc. | Tunable variant immunoglobulin superfamily domains and engineered cell therapy |
| JP2019507180A (ja) | 2016-03-04 | 2019-03-14 | アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ | がんに対する組合せ療法 |
| US11078282B2 (en) | 2016-04-15 | 2021-08-03 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| JP7071288B2 (ja) | 2016-05-18 | 2022-05-18 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| US11339201B2 (en) | 2016-05-18 | 2022-05-24 | Albert Einstein College Of Medicine | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| GB201619652D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel polypeptides |
| MX2019007611A (es) | 2016-12-22 | 2020-07-29 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso. |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| EP3576744A1 (en) | 2017-02-01 | 2019-12-11 | Medivir Aktiebolag | Therapeutic applications of malt1 inhibitors |
| CN118453840A (zh) | 2017-03-15 | 2024-08-09 | 库尔生物制药有限公司 | 用于调节免疫应答的方法 |
| CN110662758A (zh) | 2017-03-16 | 2020-01-07 | 高山免疫科学股份有限公司 | Cd80变体免疫调节蛋白及其用途 |
| WO2018170023A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
| CN110709421A (zh) | 2017-05-02 | 2020-01-17 | 鳄鱼生物科学公司 | 针对ox40和ctla-4的双特异性抗体 |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| PT3697810T (pt) | 2017-10-18 | 2026-02-19 | Alpine Immune Sciences Inc | Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados |
| BR112020013236A2 (pt) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| US12221459B2 (en) | 2018-03-09 | 2025-02-11 | Medivir Ab | Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| EP3887394A2 (en) | 2018-11-30 | 2021-10-06 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| KR20220044495A (ko) | 2019-07-04 | 2022-04-08 | 치루 레고르 테라퓨틱스 인코포레이티드 | Hpk1 억제제 및 그의 용도 |
| US12565517B2 (en) | 2019-10-08 | 2026-03-03 | Genefrontier Corporation | Cyclic peptide having CTLA-4 inhibitory activity and use thereof |
| TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| GB202103122D0 (en) | 2021-03-05 | 2021-04-21 | Univ London Queen Mary | Treatment |
| GB202103673D0 (en) | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| EP4472734A1 (en) | 2022-02-03 | 2024-12-11 | C4X Discovery Limited | Heterocyclic derivatives as malt1 inhibitors |
| EP4482962A1 (en) | 2022-02-24 | 2025-01-01 | IO Biotech ApS | Nucleotide delivery of cancer therapy |
| GB202207050D0 (en) | 2022-05-13 | 2022-06-29 | C4X Discovery Ltd | Therapeutic compounds |
| WO2025104412A1 (en) | 2023-11-15 | 2025-05-22 | C4X Discovery Limited | Therapeutic compounds |
| WO2025104411A1 (en) | 2023-11-15 | 2025-05-22 | C4X Discovery Limited | Therapeutic compounds |
| WO2025137168A2 (en) | 2023-12-19 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Salt and solid forms of a hpk1 inhibitor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US6130316A (en) | 1993-07-26 | 2000-10-10 | Dana Farber Cancer Institute | Fusion proteins of novel CTLA4/CD28 ligands and uses therefore |
| EP1186300A1 (en) | 1996-03-20 | 2002-03-13 | Bristol-Myers Squibb Company | Pharmaceutical compositions useful for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| WO2002048351A2 (en) | 2000-12-12 | 2002-06-20 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
| EP1504098B2 (en) | 2002-05-17 | 2011-02-09 | Alligator Bioscience AB | A method for in vitro molecular evolution of protein function |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| GB2432366B (en) | 2005-11-19 | 2007-11-21 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
| GB0920258D0 (en) * | 2009-11-19 | 2010-01-06 | Alligator Bioscience Ab | New medical agents and use thereof |
-
2013
- 2013-06-27 GB GBGB1311475.6A patent/GB201311475D0/en not_active Ceased
-
2014
- 2014-06-25 JP JP2016522479A patent/JP6621741B2/ja not_active Expired - Fee Related
- 2014-06-25 WO PCT/EP2014/063442 patent/WO2014207063A1/en not_active Ceased
- 2014-06-25 US US14/901,202 patent/US9834589B2/en not_active Expired - Fee Related
- 2014-06-25 EP EP14732247.3A patent/EP3013854B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526885A5 (enExample) | ||
| FI3352776T3 (fi) | Htt-repressoreita ja niiden käyttötapoja | |
| HK1201727A1 (en) | Anticancer fusion protein | |
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| AR086360A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| JP2017506217A5 (enExample) | ||
| JP2016529215A5 (enExample) | ||
| JP2017518037A5 (enExample) | ||
| NZ603623A (en) | Tcr complex immunotherapeutics | |
| PH12013500050A1 (en) | Anticancer fusion protein | |
| JO3476B1 (ar) | بروتينات مندمجة لعلاج الاضطرابات الايضية | |
| BR112013029409A2 (pt) | "produto de peptídeo compreendendo tensoativo ligado de forma covalente a peptídeo, composição farmacêutica que o compreende, bem como uso de produto de peptídeo no tratamento de condição associada à resistência à insulina, doença cardiovascular e diabetes" | |
| JP2014088414A5 (enExample) | ||
| MX2015009781A (es) | Sistemas y metodos para soporte de decision clinica. | |
| PH12013500410B1 (en) | Vegf-binding molecules | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| JP2017501381A5 (enExample) | ||
| MX395266B (es) | Composición farmacéutica que contiene, como ingrediente activo, proteína de fusión en la cual péptido tumor-penetrante y el agente anti-angiogénesis están fusionados, para prevenir y tratar cáncer o enfermedades relacionadas con la angiogénesis. | |
| JP2006518372A5 (enExample) | ||
| WO2016004906A3 (zh) | 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用 | |
| PL393578A1 (pl) | Przeciwnowotworowe białko fuzyjne | |
| MX337436B (es) | Proteina de funsion anticancer. | |
| MX2014008028A (es) | Proteina de fusion anticancerigena. | |
| JP2016502515A5 (enExample) | ||
| CN104245736A (zh) | 抗人死亡受体5胞外区的人源化单克隆抗体 |